Free tesamorelin reconstitution calculator. Enter vial size (2-5 mg), BAC water volume, and dose to get concentration, syringe units, and doses per vial. Includes the FDA-approved 2 mg daily protocol, visceral fat reduction dosing, and GHRH comparison. Verify tesamorelin quality with independent lab test data on Peptigrity.
A 5 mg vial of tesamorelin reconstituted with 1 mL of bacteriostatic water gives a concentration of 5.0 mg/mL, or 50 mcg per unit on a U-100 syringe. For a 2 mg dose, draw the syringe to 40.0 units (0.40 mL). At that dose the vial provides about 2.5 doses.
Defaults: 5 mg vial + 1 mL from this page's reconstitution quick reference; 2 mg is the "Standard (FDA)" row of this page's dose ladder, used here for arithmetic only.
Draw the syringe up to
That's one 2 mg dose. Add 1 mL of water to your 5 mg vial first.
| Step | Dose | Draw on a U-100 | Doses per vial |
|---|---|---|---|
| Low dose | 1 mg | 20 units | 5 |
| Standard (FDA) | 2 mg | 40 units | 2 |
Tap any row to load that dose into the calculator above.
Tesamorelin is a 44-amino-acid GHRH analogue - the only FDA-approved peptide in this calculator suite (marketed as Egrifta SV for HIV-associated lipodystrophy). The approved dose is 2 mg subcutaneously once daily. Community protocols vary from this anchor.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| FDA-approved | 2 mg (2,000 mcg) | 1× daily | Ongoing (clinical trials: 26-52 weeks) | Established in Phase 3; subcutaneous abdomen |
| Standard community | 1-2 mg | 1× daily | 8-12 weeks on / 4 weeks off | Cycling to manage GH receptor sensitivity |
| 5-on-2-off | 2 mg | 5 days on / 2 off | 12 weeks | Reduces weekly consumption by ~29% |
| Tesa + Ipa stack | 1-2 mg tesa + 200-300 mcg ipa | 1× daily (evening) | 8-12 weeks | GHRH + GHRP synergy; see blend calculator |
| Vial | BAC Water | Conc. | 1 mg Draw | 2 mg Draw | Doses (2 mg) |
|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 20 units | 40 units | 2.5 |
| 5 mg | 2.5 mL | 2 mg/mL | 50 units | 100 units (full) | 2.5 |
| 10 mg | 2 mL | 5 mg/mL | 20 units | 40 units | 5 |
| 10 mg | 5 mL | 2 mg/mL | 50 units | 100 units (full) | 5 |
Common: 5 mg vial + 1 mL BAC water = 5 mg/mL. The FDA 2 mg dose = 40 units - a clean, manageable draw. At 2 mg/mL (2.5 mL BAC), the same dose fills the entire syringe. For technique, see reconstituting peptides step by step.
| Vial | 1 mg / day | 2 mg / day | 2 mg 5-on-2-off |
|---|---|---|---|
| 5 mg | 5 days | 2.5 days | ~3.5 days |
| 10 mg | 10 days | 5 days | ~7 days |
Tesamorelin is consumed rapidly - a 30-day cycle at 2 mg daily requires 12 × 5 mg vials or 6 × 10 mg vials. The 5-on-2-off protocol reduces this to approximately 9 × 5 mg vials per month.
| Property | Tesamorelin | Sermorelin | CJC-1295 (no DAC) |
|---|---|---|---|
| Full name | Modified GHRH(1-44) | GHRH(1-29) | Modified GHRH(1-29) + 4 AA changes |
| Amino acids | 44 | 29 | 29 (modified) |
| FDA status | Approved (Egrifta SV) | NDA withdrawn (2008) | Not approved |
| Modification | Trans-3-hexenoic acid at N-terminal | None (truncated native) | 4 amino acid substitutions for DPP-IV resistance |
| Half-life | ~26 min (longer effective due to modification) | ~10-20 min | ~30 min |
| Typical dose | 2 mg daily | 200-500 mcg daily | 100-300 mcg 1-2× daily |
| Clinical data | Phase 3 trials (n=800+) | Limited clinical | Minimal clinical |
| WADA status | Prohibited (S2) | Prohibited (S2) | Prohibited (S2) |
The tesamorelin + ipamorelin combination pairs a GHRH analogue with a selective GHRP. Tesamorelin provides the releasing hormone signal while ipamorelin triggers GH release through the ghrelin receptor - without elevating cortisol or prolactin. This combination is available as pre-made blend vials from several peptide vendors. For blend dosing, use the Blend Calculator with the Tesa + Ipa preset.
Tesamorelin is a 44-amino-acid peptide with MW of approximately 5,135.9 Da. Check the CoA for ≥98% HPLC purity and mass spectrometry confirming MW. The trans-3-hexenoic acid modification at the N-terminal should be verifiable. Cross-reference with independent lab test results. For CoA interpretation, see red flags in peptide CoAs.
At 5 mg/mL (5 mg + 1 mL BAC water): 2 mg = 40 units. At 2 mg/mL (5 mg + 2.5 mL): 2 mg = 100 units (a full syringe). Use 1 mL BAC water for cleaner draws.
The FDA-approved dose is 2 mg subcutaneously once daily, based on Phase 3 trials for HIV-associated lipodystrophy. This is the only FDA-approved peptide in the Peptigrity tool suite.
Both are GHRH analogues. Tesamorelin is FDA-approved (44 amino acids, trans-3-hexenoic acid modification) with robust clinical data. Sermorelin is shortened GHRH(1-29) with its NDA withdrawn. Tesamorelin has a longer effective half-life.
Yes - the Tesa + Ipa stack is one of the most popular GHRH + GHRP combinations. Use the Blend Calculator for combined vial dosing.
At 2 mg daily: 12 × 5 mg vials or 6 × 10 mg vials per 30 days. The 5-on-2-off protocol reduces this to ~9 × 5 mg vials.
Yes. Tesamorelin is on the WADA Prohibited List (S2) as a GH-releasing factor, prohibited in- and out-of-competition.
A 5 mg vial at 2 mg/day lasts about 2.5 days. A 10 mg vial lasts 5 days. Tesamorelin is one of the fastest-consumed peptides - plan supply accordingly.